<DOC>
	<DOC>NCT00231790</DOC>
	<brief_summary>Overactive bladder is very prevalent in postmenopausal women. The current study is designed to investigate whether a new drug may offer safe and effective treatment.</brief_summary>
	<brief_title>A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)</brief_title>
	<detailed_description>Clinical development of MK-0634 was discontinued. Study MK-0634-027 was a safety follow-up study to determine if there were any ocular effects of MK-0634 in participants from the United Kingdom who were exposed to MK-0634 during the 007 study.</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<criteria>Postmenopausal females (ages 4074) with predominantly urge urinary incontinence overactive bladder episodes. Patients must meet minimum eligibility requirements (e.g., average number of micturitions/day) based on screening diary cards. Patients must not suffer from diabetes insipidus Hyperglycemia Hypercalcemia Orthostatic hypotension Active/recurrent urinary tract infections (&gt;6 episodes per year) Patients must be willing to discontinue their current OAB medication therapy.</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>